News Conference News HFSA 2025 Too Few HF Patients on Guideline-Directed Medical Therapy in VA System Yael L. Maxwell October 06, 2025
News Conference News HFSA 2025 Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74 Yael L. Maxwell September 30, 2025
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News HFSA 2024 ‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF Michael O'Riordan October 03, 2024
News Conference News HFSA 2024 ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM L.A. McKeown October 02, 2024
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Conference News HFSA 2023 Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships Shelley Wood October 13, 2023
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2021 Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF Michael O'Riordan September 14, 2021
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Conference News HFSA 2019 Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention L.A. McKeown September 24, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019